Melanocortin receptor agonist · Fact sheet
Melanotan II
Also known as Melanotan-2 · MT-II · MT2
Melanotan II is an unapproved peptide associated with skin pigmentation and sexual effects. Small trials reported erections and nausea; serious case reports raise additional concerns and do not establish a safe tanning use.
What is Melanotan II?
Melanotan II activates melanocortin pathways. It is different from the approved drugs afamelanotide and bremelanotide, and their approvals do not transfer to it.
Benefits & claims
Tanning, increased sexual desire, and erectile effects drive interest. A pigmentation change is not evidence of protection from ultraviolet damage.
What the evidence supports
- Small studies found more erectile responses than placebo, with increased sexual desire in one study.
- These experimental observations are not an FDA-approved indication.
Research areas
- Erectile responses
- Sexual desire
- Melanocortin signaling
Dosage & frequency
No established human regimenThere is no FDA-approved melanotan II tanning or sexual-function regimen. Early human studies do not establish safe cosmetic use.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Melanotan II is distinct from approved bremelanotide and from afamelanotide.
Interactions & precautions
- An established human interaction profile for cosmetic tanning use is lacking; early experiments do not establish combination safety.
What is still unresolved
- A safe dose, frequency, product standard, and long-term skin or cardiovascular risk profile remain unestablished.
Side effects & risks
- Nausea, yawning, stretching, and reduced appetite were reported in the small trials.
- FDA cites serious case reports, including prolonged erections and melanoma; such reports do not establish incidence or causation.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceTwo small controlled crossover studies in men with erectile dysfunction found erectogenic effects. They do not establish everyday tanning safety, lasting sexual benefit, or applicability to other populations.
Studies
Ten-person crossover study of erections, desire, and tolerability.
Ten-person controlled crossover study; short follow-up and narrow population.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Greater libido with unwanted facial darkening
An author described better libido, mood and energy over two weeks, but unexpectedly dark facial pigmentation and much darker freckles, which prompted them to stop.
Reported use in this account
- Product
- Product described as melanotan II
- Amount
- 0.25 mg
- Frequency
- Every day, as reported
- Route
- Not specified clearly
- Duration
- About two weeks
The product, UV exposure and skin changes were not clinically verified. This cannot identify or rule out a concerning mole change.
Read the original accountMood: reported experiences
Greater libido with unwanted facial darkening
An author described better libido, mood and energy over two weeks, but unexpectedly dark facial pigmentation and much darker freckles, which prompted them to stop.
Reported use in this account
- Product
- Product described as melanotan II
- Amount
- 0.25 mg
- Frequency
- Every day, as reported
- Route
- Not specified clearly
- Duration
- About two weeks
The product, UV exposure and skin changes were not clinically verified. This cannot identify or rule out a concerning mole change.
Read the original accountDigestion: reported experiences
Tanning and libido changes, with unwanted pigmentation
A commenter described a tan and increased libido, alongside flushing, darkened freckles or moles, inconvenient spontaneous erections and occasional day-long illness.
Amount, frequency, route and duration could not be confirmed for this account.
This retrospective account does not verify product contents, lesion safety or the cause of illness.
Read the original accountPigmentation persisted without the hoped-for libido effect
A person describing intermittent exposure over two years reported darker hair and skin, recurring nausea after breaks, and little libido improvement; they wondered about weaker erections.
Reported use in this account
- Product
- Products described as melanotan II
- Amount
- 500 mcg stated for one pre-bed injection; exposure varied over time
- Frequency
- Varied; the account describes differing schedules rather than one continuous schedule
- Route
- Injection; specific route not stated
- Duration
- A little over two years, with about five months off in total
Other exposures described: Tadalafil; Varying products and sun exposure
Tadalafil, varying products and other possible causes were involved. The suggested receptor explanation was speculation, not a verified injury or mechanism.
Read the original accountSkin: reported experiences
Tanning and libido changes, with unwanted pigmentation
A commenter described a tan and increased libido, alongside flushing, darkened freckles or moles, inconvenient spontaneous erections and occasional day-long illness.
Amount, frequency, route and duration could not be confirmed for this account.
This retrospective account does not verify product contents, lesion safety or the cause of illness.
Read the original accountGreater libido with unwanted facial darkening
An author described better libido, mood and energy over two weeks, but unexpectedly dark facial pigmentation and much darker freckles, which prompted them to stop.
Reported use in this account
- Product
- Product described as melanotan II
- Amount
- 0.25 mg
- Frequency
- Every day, as reported
- Route
- Not specified clearly
- Duration
- About two weeks
The product, UV exposure and skin changes were not clinically verified. This cannot identify or rule out a concerning mole change.
Read the original accountPigmentation persisted without the hoped-for libido effect
A person describing intermittent exposure over two years reported darker hair and skin, recurring nausea after breaks, and little libido improvement; they wondered about weaker erections.
Reported use in this account
- Product
- Products described as melanotan II
- Amount
- 500 mcg stated for one pre-bed injection; exposure varied over time
- Frequency
- Varied; the account describes differing schedules rather than one continuous schedule
- Route
- Injection; specific route not stated
- Duration
- A little over two years, with about five months off in total
Other exposures described: Tadalafil; Varying products and sun exposure
Tadalafil, varying products and other possible causes were involved. The suggested receptor explanation was speculation, not a verified injury or mechanism.
Read the original accountHair: reported experiences
Pigmentation persisted without the hoped-for libido effect
A person describing intermittent exposure over two years reported darker hair and skin, recurring nausea after breaks, and little libido improvement; they wondered about weaker erections.
Reported use in this account
- Product
- Products described as melanotan II
- Amount
- 500 mcg stated for one pre-bed injection; exposure varied over time
- Frequency
- Varied; the account describes differing schedules rather than one continuous schedule
- Route
- Injection; specific route not stated
- Duration
- A little over two years, with about five months off in total
Other exposures described: Tadalafil; Varying products and sun exposure
Tadalafil, varying products and other possible causes were involved. The suggested receptor explanation was speculation, not a verified injury or mechanism.
Read the original accountSexual function: reported experiences
Tanning and libido changes, with unwanted pigmentation
A commenter described a tan and increased libido, alongside flushing, darkened freckles or moles, inconvenient spontaneous erections and occasional day-long illness.
Amount, frequency, route and duration could not be confirmed for this account.
This retrospective account does not verify product contents, lesion safety or the cause of illness.
Read the original accountGreater libido with unwanted facial darkening
An author described better libido, mood and energy over two weeks, but unexpectedly dark facial pigmentation and much darker freckles, which prompted them to stop.
Reported use in this account
- Product
- Product described as melanotan II
- Amount
- 0.25 mg
- Frequency
- Every day, as reported
- Route
- Not specified clearly
- Duration
- About two weeks
The product, UV exposure and skin changes were not clinically verified. This cannot identify or rule out a concerning mole change.
Read the original accountPigmentation persisted without the hoped-for libido effect
A person describing intermittent exposure over two years reported darker hair and skin, recurring nausea after breaks, and little libido improvement; they wondered about weaker erections.
Reported use in this account
- Product
- Products described as melanotan II
- Amount
- 500 mcg stated for one pre-bed injection; exposure varied over time
- Frequency
- Varied; the account describes differing schedules rather than one continuous schedule
- Route
- Injection; specific route not stated
- Duration
- A little over two years, with about five months off in total
Other exposures described: Tadalafil; Varying products and sun exposure
Tadalafil, varying products and other possible causes were involved. The suggested receptor explanation was speculation, not a verified injury or mechanism.
Read the original accountApproval status
Melanotan II is not FDA approved. It is not interchangeable with approved melanocortin medicines, and the cited small trials do not establish a current approval pathway.
No FDA-approved Melanotan II product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term skin and cancer outcomes
- The frequency of serious adverse events
- Safety across populations and unverified products
Summary
Melanotan II has observable biological effects and substantial unresolved risks; a tan or sexual response is not proof of safety.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- pubmedMelanotan II in men with organic erectile dysfunction
Ten-person crossover study of erections, desire, and tolerability.
- pubmedMelanotan II in psychogenic erectile dysfunction
Ten-person controlled crossover study; short follow-up and narrow population.